~~<i id='6C55887318'><strike id='6C55887318'><tt id='6C55887318'><pre id='6C55887318'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：Wikipedia 2025-10-01 18:33:26 - browse：1743

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Meadows told special counsel he could not recall Trump ever declassifying Mar

Wikipedia

explore

knowledge

leisure time

hotspot

AdobeInvestorsarestartingtobackstartupsthatofferprivacyandsecurityservicestobolsterhealthAIproductsa

WSS

Health AI adoption puts security, privacy startups on investors' radar

5 to watch: Tech startups trying to solve health care's staffing crisis

Gene editing the human germline: What are the risks?

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Abortion policy in the spotlight at Republican debate

How the drug

focus

leisure time

Wikipedia

Hepatitis C has a cure — but many Americans still lack access to it

Health officials lay out plans to cope with respiratory virus season

How to save PrEP access — and even expand it

Wegovy improves function in certain heart failure patients

The cancer drug shortage isn’t new — and neither are the solutions

Orchard's therapy for neuron disease in children wins FDA approval

BioMarin wins approval for gene therapy to treat hemophilia A

PBMs are inflating the cost of generic drugs. They must be reined in

Anesthesiologist group: stop taking Ozempic before surgery

CVS Caremark has created a new ploy: the drug ‘rebate credit’

explore

Kellogg’s is going to war over Mexico’s nutrition label rules

UnitedHealth increases loan offers after Change Healthcare outage

Abortion policy in the spotlight at Republican debate

Intellia plays down concerns on accidental germline transmission

Creating egg and sperm cells from stem cells raises ethical issues

National associations that represent hospice owe an apology

knowledge

leisure time

leisure time

hotspot